Mitochondrial Complex I Deficiency Nuclear Type 27 C4748826
A genetic condition affecting cellular energy production, potentially impacting muscles, brain, and other organs. Tissues with high energy demands are often involved. Care is supportive.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Optic atrophy (vision loss)
Fatigue or weight changes
(metabolic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Lactic acidosis
(metabolic)Muscle weakness (hypotonia)
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Comprehensive Cardiac Surveillance
Regular cardiac monitoring including echocardiograms and Holter monitors to detect cardiomyopathy, arrhythmias, or conduction abnormalities common in mitochondrial complex I deficiency. Early detection allows timely intervention.
Drug therapy with clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Mitochondrial Support Supplement Cocktail
Combination therapy including CoQ10, L-carnitine, alpha-lipoic acid, and B-complex vitamins designed to support multiple aspects of mitochondrial function and electron transport chain activity.
Additional treatment options
Anti-Inflammatory Mediterranean Diet
An antioxidant-rich dietary approach emphasizing olive oil, fish, vegetables, and fruits to reduce oxidative stress on mitochondria. May help protect remaining complex I function from further damage.
dietarySymptomatic Seizure Management
Anticonvulsant medications tailored to seizure type for patients presenting with epilepsy secondary to mitochondrial dysfunction. Drug selection considers minimal mitochondrial toxicity.
medicationOccupational Therapy for Daily Function
Therapeutic interventions focusing on maintaining activities of daily living, energy conservation techniques, and adaptive equipment to maximize independence despite progressive mitochondrial disease.
physical_therapyWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Mitochondrial Complex I Deficiency Nuclear Type 27 C4748826?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Mitochondrial Complex I Deficiency Nuclear Type 27 C4748826. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy